Circ Cardiovasc Interv

Slides:

Advertisements

Similar presentations

TLR Funnel plot (according to outcomes) for studies included in the meta-analysis Death A TVR B MACE DC SE(log OR)

Advertisements

ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.

Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.

Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Implantation of a Drug-Eluting Stent With a Different.

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reduced-Function CYP2C19 Genotype and Risk of Adverse.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting.

Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Coronary Anatomy and Stenting Technique.

Date of download: 9/16/2016 Copyright © The American College of Cardiology. All rights reserved. From: 5-Year Clinical Outcomes of the ARTS II (Arterial.

From: Sustained Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Lesions: 2-Year Follow-Up From the Zilver PTX Randomized and Single-Arm.

From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.

Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE

Evaluation of XIENCE V Everolimus-Eluting and Taxus Express2 Paclitaxel-Eluting Coronary Stents in Patients With Jailed Side Branches From the SPIRIT.

Figure 1 Flow diagram of systematic review

Usefulness of Preprocedure High-Sensitivity C-Reactive Protein to Predict Death, Recurrent Myocardial Infarction, and Stent Thrombosis According to Stent.

Supplementary Table 1 Independent Predictors of 2-Year Mortality

12 Month Outcomes in Patients with Diabetes Mellitus Implanted with a Resolute Zotarolimus-eluting Stent: Initial Results from the RESOLUTE Global Clinical.

NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.

Copyright © 2013 American Medical Association. All rights reserved.

Volume 54, Issue 1, Pages (August 2009)

Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.

For the HORIZONS-AMI Investigators

Comparison of Outcomes in Patients With Versus Without Diabetes Mellitus After Revascularization With Everolimus- and Sirolimus-Eluting Stents (from the.

Long-term clinical outcome of elderly patients with acute coronary syndrome treated with early percutaneous coronary intervention: Insights from the BASE.

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Sex-Related Differences in Fractional Flow Reserve–Guided Treatment

Circ Cardiovasc Interv

Optima DES system: The stent has multiple grooves (reservoirs) on its abluminal surface into which the drug is loaded. Optima DES system: The stent has.

Circ Cardiovasc Interv

Unadjusted 3-year cumulative incidence of adverse events after saphenous vein graft (SVG) percutaneous coronary intervention (PCI) with embolic protection.

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Interv

New Frontiers in Cardiology

Circ Cardiovasc Interv

Ahead of the Curve by Alun D. Hughes Hypertension Volume 64(5):

Circ Cardiovasc Interv

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Catheter-Based Treatment of Coronary Artery Disease

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

American College of Cardiology Presented by Dr. Stephan Windecker

For the HORIZONS-AMI Investigators

For the HORIZONS-AMI Investigators

J. Trevor Posenau, MD, Daniel M. Wojdyla, MS, Linda K

The American College of Cardiology Presented by Dr. Raimund Erbel

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.

Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.

Tornado diagram of one-way deterministic sensitivity analysis.

John A. Bittl et al. JACC 2016;68:

Svend A. Mortensen et al. JCHF 2014;2:

Do the EXCEL and NOBLE Trial Results Change Meta-Analysis Findings?

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

Seung-Yul Lee et al. JCIN 2018;j.jcin

Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death.

(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.

IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.

Christian Madelaire et al. JCHF 2018;6:

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Pamela E. Scott et al. JACC 2018;71:

Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.

Performance of the Manchester Acute Coronary Syndromes decision rule in the validation study. Performance of the Manchester Acute Coronary Syndromes decision.

Presentation transcript:

Circ Cardiovasc Interv Mesh-Covered Embolic Protection Stent Implantation in ST-Segment–Elevation Myocardial Infarction by Dariusz Dudek, Artur Dziewierz, Sorin J. Brener, Alexandre Abizaid, Béla Merkely, Ricardo A. Costa, Eli Bar, Tomasz Rakowski, Ran Kornowski, Ovidiu Dressler, Andrea Abizaid, Sigmund Silber, and Gregg W. Stone Circ Cardiovasc Interv Volume 8(2):e001484 January 20, 2015 Copyright © American Heart Association, Inc. All rights reserved.

Time-to-event curves for (A) all-cause mortality, (B) major adverse cardiac events (MACE), (C) ischemia-driven target lesion revascularization (TLR), and (D) definite or probable stent thrombosis. Time-to-event curves for (A) all-cause mortality, (B) major adverse cardiac events (MACE), (C) ischemia-driven target lesion revascularization (TLR), and (D) definite or probable stent thrombosis. BMS indicates bare metal stent; CI, confidence interval; DES, drug-eluting stent; and HR, hazard ratio. Dariusz Dudek et al. Circ Cardiovasc Interv. 2015;8:e001484 Copyright © American Heart Association, Inc. All rights reserved.